New scientific study -which used #OncoDEEP- shows that molecular biomarker testing could be extended to patients with head and neck squamous cell carcinoma #HNSCC before being treated with #immunotherapy oncodna.com/en/company/act… #genomicprofiling #cancerresearch #precisiononcology

Great insights from OncoDNA, the cancer theranostic company CEO into how the company’s revenue grew more than 180% in four year, resulting in a #Fast50BE win. ➡️ L’Echo: lecho.be/partner/deloit…... lnkd.in/e3fpnFz

From WGS to targeted gene panel analysis, MERCURY combines the integrated analysis of both DNA-seq and RNA-seq data to give you access to the precise molecular profile of a tumor. 👉 Visit MERCURY webpage to request a demo: ow.ly/AbLg50DBCU4 #NGS #cancer #bioinformatics

How to select the right #biomarkertest to learn about an individual cancer and guide selection of the best treatment? youtube.com/watch?v=tYXCbC… #ctDNA #genomicprofiling #nextgenerationsequencing #MDIP

When is a new biopsy preferable for biomarker analysis? ow.ly/OKpw50DHJH3 #MDIP #biomarkertesting #BRAF #EGFR #precisiononcology

Did you know that 1 in 4 new cancer cases diagnosed across Europe each year are rare types of cancer? Rare is not as rare as you may think. Join us in support of #rarediseaseday! Dr. Caramelo

Deux sociétés belges, OncoDNA et myNEO, vont développer des immunothérapies anticancéreuses personnalisées pour les patients en impasse thérapeutique, en se basant sur l'ARN messager. BioWin @essenscia_FR Wallonia Export & Investment Agency @SRIWGroup Sambrinvest lecho.be/innover/genera…

Institut Curie & OncoDNA test the clinical utility of personalized liquid biopsy in head and neck cancers techtransfer.institut-curie.org/news/partnersh…

It’s new. It’s efficient. It’s personalized. Let us introduce you to our new #OncoDEEP a comprehensive #biomarkertest designed to support rapid & targeted treatment decisions for advanced cancer youtube.com/watch?v=G9EhsD… #precisionmedicine #moleculardiagnostics #genomicprofiling

New collaboration with the Institut Jules Bordet Instituut as part of the BrainStorm study. 🤒 600 patients with solid tumors 🏥 sites in FR, BE, LU 💧 CSF ctDNA 🧬 large and targeted NGS panels 🏆 new targets for therapy and less invasive biomarkers ow.ly/V2nE50Fc046 #cancerresearch

L'Institut Jules Bordet collabore avec OncoDNA pour étudier la biologie des #métastases #cérébrales à partir d’analyses personnalisées du liquide #céphalorachidien Nuria Kotecki, MD oncodna.com/en/company/act…

Proud that our OncoFOLLOW has been chosen as personalized liquid biopsy solution for this study managed by the Bordet Institute in several European countries. After ctDNA in the blood, we also demonstrate our abilities in cerebrospinal fluid!

We've completed our portfolio with genomic services & analysis tools. With IntegraGen on board, we can now help you integrate #NGS technology into your research projects and explore enormous volume of data in a fast and easy way. integragen.com #geneticdiseases #cancer

Another success of the OncoDNA Dream team, delivering the promises of #personalizedmedicine step by step OncoDNA Bayer | Pharmaceuticals

Proud to start this partnership with Sophia Genetics : combination of Sophia DDM and our OncoKDM solution to provide the most advanced interpretation solution for complex oncology gene panels genomeweb.com/business-news/… Marc Coucke (finally working together 😀)

La société radiomics.bio va utiliser les compétences de OncoDNA dans son étude contre le #cancer du poumon. Deux approches: #IA et #biomarqueurs vont se combiner au bénéfice du patient via : bit.ly/3d01Z3l via L'Echo #DW4AI JP Detiffe - OncoDNA

👏🏻👏🏻 OncoDNA

OncoDNA s'allie avec l'américain C2i Genomics dans la médecine de précision ➡lecho.be/entreprises/ph… ✍️ Par Gosset Olivier | OncoDNA C2i Genomics #biopsie #cancer #ArtificialIntelligence

#BSMO24 Brigitte Maes gives an update on the Belgian Society of Medical Oncology #BALLETT study offering comprehensive genomic profiling with ⁦Illumina⁩ TSO500 🔹Actionable variants detected in 83% of pts 🔹Treatment recommendations in 70% of pts ➡️ followed in 21% ⁦OncoAlert⁩ ⁦Belgian Society of Medical Oncology⁩